Establishment and Characterisation of New Immunoreagents for Diagnosis of Neurodegenerative Disease

dc.contributor.authorEriksson, Matilda
dc.contributor.departmentChalmers tekniska högskola / Institutionen för biologi och biotekniksv
dc.contributor.examinerMolin, Mikael
dc.contributor.supervisorLidqvist, Maria
dc.date.accessioned2022-08-12T12:58:33Z
dc.date.available2022-08-12T12:58:33Z
dc.date.issued2022sv
dc.date.submitted2020
dc.description.abstractNeurodegenerative diseases are a collection of disorders which can develop any time in adulthood, but with the majority occurring in the elderly population. A common denominator for these diseases is the gradual degradation of neurons in the central nervous system, often taking place long before the manifestation of clinical symptoms. One of the proteins taking part in this process is called neurofilament light, which upon degradation can be found both in the cerebrospinal fluid as well as the blood. In vivo diagnostic tools utilising antibodies have been developed for the detection of NF-L in the CSF, allowing for earlier diagnosis. However, for screening to be able to take place at local healthcare centers, a diagnostic test for NF-L in blood would be more beneficial. Since the concentration of the antigen is much lower in the blood compared to the CSF, antibodies with high specificity and sensitivity are necessary. The aim of this project was to establish high affinity monoclonal antibodies against the protein neurofilament light, specifically when present in plasma, using classic hybridoma technology. Mice were immunised with full length bovine NF-L as well as two shorter custom made peptides, originating from the Coil-2 region of NF-L, having shown to be a valuable epitope sight for clinically effective antibodies. Over 20 hybridomas producing relevant antibodies were established, detected through ELISA screens. All succesfull hybridomas originated from the mice immunised with peptides. The majority of the established antibodies had the desired isotypes and a few had a strong response towards full length bovine NF-L, indicating clinical relevance. To conclude, a number of antibodies with the potential of being used in a sandwich ELISA diagnostic test for the detection of NF-L in blood have been established. These antibodies were proven to recognise the native form of bovine NF-L, epitope mapped to the clinically relevant Coil 2 region and were not reactive to other proteins present in clinical samples of CSF or serum. This project was performed at Fujirebio AB located in Gothenburg, Sweden.sv
dc.identifier.coursecodeBBTX03sv
dc.identifier.urihttps://hdl.handle.net/20.500.12380/305335
dc.language.isoengsv
dc.setspec.uppsokLifeEarthScience
dc.subjectNeurofilament lightsv
dc.subjectbiomarkersv
dc.subjectmonoclonal antibodiessv
dc.subjecthybridoma technologysv
dc.subjectELISAsv
dc.titleEstablishment and Characterisation of New Immunoreagents for Diagnosis of Neurodegenerative Diseasesv
dc.type.degreeExamensarbete för masterexamensv
dc.type.uppsokH
local.programmeBiotechnology (MPBIO), MSc
Ladda ner
Original bundle
Visar 1 - 1 av 1
Hämtar...
Bild (thumbnail)
Namn:
Master's Thesis_Matilda Eriksson.pdf
Storlek:
22.02 MB
Format:
Adobe Portable Document Format
Beskrivning:
License bundle
Visar 1 - 1 av 1
Hämtar...
Bild (thumbnail)
Namn:
license.txt
Storlek:
1.51 KB
Format:
Item-specific license agreed upon to submission
Beskrivning: